Chronic kidney disease (CKD) is undergoing a paradigm shift as genetic insights have reshaped its diagnosis and management. Rare monogenic variants explain a growing number of early onset and familial cases, while polygenic risk scores offer new tools for risk stratification. Emerging research, especially from Korean cohorts, has revealed modifiable gene-environment interactions and integrates genomics with metabolomics to uncover disease-specific pathways. Genetic testing plays a pivotal role in clinical reclassification and therapeutic decision-making. With the expansion of kidney genetics clinics, generalists and specialists must adapt to this era of precision. The journey from genes to clinics is no longer conceptual; rather, it redefines CKD care.
Yang et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: